ManRos Therapeutics

"From Sea to Pharmacy"

Executive Summary

Therapeutic applications of protein kinase inhibitors derived from marine organisms: cancers, Alzheimer's disease, polycystic kidney disease

Kinase inhibition is one of the most promising approach for the discovery of new clinical drugs

Over the last decade, inhibition of protein phosphorylation (performed by kinases) has emerged as a major opportunity for novel drug development in numerous therapeutic areas. Beyond the attention drawn to the subject with the award of three independent Nobel Prizes, leading pharmaceutical companies are investigating the field (Novartis, Pfizer, GSK, etc.).

A team of renowned kinase inhibitors specialists

ManRos Therapeutics has been founded by Dr. Laurent MEIJER, Research Director at the CNRS and Pr. Hervé GALONS, Professor of Organic Chemistry at the Université Paris Descartes. Dr. Laurent MEIJER is a world-renowned kinases specialist. He identified roscovitine (seliciclib), a molecule currently undergoing phase 2b clinical trials against cancers. Emmanuel DE MAISTRE joined them as CEO of the company.

An preclinical pipeline of validated drug candidates

Following the discovery of roscovitine, ManRos Therapeutics founders and collaborators have identified and characterized several new families of kinase inhibitors (some of which from marine origin), with significant improvements over roscovitine or competitive products, in terms of activity and toxicity. These promising novel drug candidates have been validated in vitro and/or in vivo, and are now undergoing pre-clinical testing. We will assemble proof of concept data, we will carry out the pharmacological optimization, the toxicity studies, and will bring the selected molecules towards clinical studies.

A first focus on three areas: oncology, CNS, kidney diseases

ManRos Therapeutics aims at bringing these pharmacological inhibitors to clinical applications where a first proof-of-concept has been established: cancers, leukemia, neurodegenerative disorders (especially Alzheimer's disease), and polycystic kidney disease (PKD). Simultaneously, the company will generate new pre-clinical projects to fill its pipeline.

ManRos at a glance

ManRos Therapeutics technology was first jointly developed in prestigious French institutional research organizations, including the CNRS.

ManRos Therapeutics is currently hosted by the Station Biologique de Roscoff and Paris Descartes University. The company plans to set up its own facilities in Roscoff (Brittany, France) and in Manhattan (NY, USA).



The drug compounds developed at ManRos Therapeutics are primarily targeted at three diseases: cancers, Alzheimer's disease and polycystic kidney disease (PKD).

Contact

Emmanuel de Maistre

ManRos Therapeutics
Place Georges Teissier - B.P. 74
F-29680 Roscoff
www.manros-therapeutics.com

ManRos Therapeutics – Perharidy Hospital, Roscoff, France



ManRos Therapeutics – East River Science Park, Manhattan, New York, USA (US subsidiary: launch expected in 2011)